NO20006194L - Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri - Google Patents

Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri

Info

Publication number: NO20006194L
Authority: NO; Norway
Prior art keywords: treatment; bowel syndrome; irritable bowel; functional dyspepsia; pharmaceutical composition
Prior art date: 1998-06-11

Application number

NO20006194A

Other languages

English (en)

Other versions

NO327738B1 (no

NO20006194D0 (no

Inventor

Per Hellstroem

Suad Efendic

Original Assignee

Per Hellstroem

Suad Efendic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-11

Filing date

2000-12-06

Publication date

2001-01-25

2000-12-06 Application filed by Per Hellstroem, Suad Efendic filed Critical Per Hellstroem

2000-12-06 Publication of NO20006194D0 publication Critical patent/NO20006194D0/no

2001-01-25 Publication of NO20006194L publication Critical patent/NO20006194L/no

2009-09-14 Publication of NO327738B1 publication Critical patent/NO327738B1/no

Links

201000006549 dyspepsia Diseases 0.000 title abstract 4
208000002551 irritable bowel syndrome Diseases 0.000 title abstract 4
239000008194 pharmaceutical composition Substances 0.000 title abstract 3
239000000126 substance Substances 0.000 title 1
230000001262 anti-secretory effect Effects 0.000 abstract 3
239000003626 gastrointestinal polypeptide Substances 0.000 abstract 3
210000001035 gastrointestinal tract Anatomy 0.000 abstract 3
239000005556 hormone Substances 0.000 abstract 3
229940088597 hormone Drugs 0.000 abstract 3
230000002586 relaxatory effect Effects 0.000 abstract 3
210000002460 smooth muscle Anatomy 0.000 abstract 3
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract 2
102100040918 Pro-glucagon Human genes 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
239000000654 additive Substances 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Nutrition Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

NO20006194A 1998-06-11 2000-12-06 Anvendelse av et gastrointestinalt peptidhormon eller et derivat derav samt farmasoytisk sammensetning NO327738B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9802080A SE9802080D0 (sv)	1998-06-11	1998-06-11	Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
PCT/SE1999/000997 WO1999064060A1 (en)	1998-06-11	1999-06-08	Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein

Publications (3)

Publication Number	Publication Date
NO20006194D0 NO20006194D0 (no)	2000-12-06
NO20006194L true NO20006194L (no)	2001-01-25
NO327738B1 NO327738B1 (no)	2009-09-14

Family

ID=20411665

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20006194A NO327738B1 (no)	1998-06-11	2000-12-06	Anvendelse av et gastrointestinalt peptidhormon eller et derivat derav samt farmasoytisk sammensetning

Country Status (19)

Country	Link
US (1)	US6348447B1 (no)
EP (2)	EP1405642A1 (no)
JP (2)	JP2002517468A (no)
AT (1)	ATE252912T1 (no)
AU (1)	AU738994B2 (no)
CA (1)	CA2321700C (no)
CZ (1)	CZ300873B6 (no)
DE (1)	DE69912434T2 (no)
DK (1)	DK1094834T3 (no)
ES (1)	ES2205845T3 (no)
HU (1)	HUP0103147A3 (no)
NO (1)	NO327738B1 (no)
NZ (1)	NZ506163A (no)
PL (1)	PL198802B1 (no)
PT (1)	PT1094834E (no)
RU (1)	RU2226402C2 (no)
SE (1)	SE9802080D0 (no)
WO (1)	WO1999064060A1 (no)
ZA (1)	ZA200004080B (no)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US9006175B2 (en) *	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
EP2280004B1 (en)	1999-06-29	2016-04-20	MannKind Corporation	Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
JP2003526671A (ja) *	2000-03-14	2003-09-09	レストラゲン，インコーポレイテッド	幽門洞−十二指腸運動性に対するグルカゴン様ペプチド‐１（７−３６）の作用
EP1274720A4 (en)	2000-04-12	2004-08-18	Human Genome Sciences Inc	FUSION PROTEINS CONTAINING ALBUMIN
CN103356996A (zh)	2000-05-19	2013-10-23	埃米林药品公司	Glp-1用于制备治疗急性冠脉综合征的药物的用途
PT1463751E (pt)	2001-12-21	2013-08-26	Human Genome Sciences Inc	Proteínas de fusão de albumina
CN1332711C (zh)	2002-02-20	2007-08-22	埃米球科技有限公司	施用glp－1分子的方法
EP1494732B1 (en)	2002-03-20	2008-01-30	MannKind Corporation	Inhalation apparatus
US20080260838A1 (en) *	2003-08-01	2008-10-23	Mannkind Corporation	Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
JP4629047B2 (ja)	2003-06-12	2011-02-09	イーライリリーアンドカンパニー	Ｇｌｐ−１アナログ複合タンパク質
CA2528375C (en)	2003-06-18	2013-11-19	Tranzyme Pharma, Inc.	Macrocyclic antagonists of the motilin receptor
US20060286129A1 (en)	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
DK1786784T3 (da)	2004-08-20	2011-02-14	Mannkind Corp	Katalyse af diketopiperazinsyntese
CN104436170B (zh)	2004-08-23	2018-02-23	曼金德公司	用于药物输送的二酮哌嗪盐
WO2006111169A1 (en) *	2005-04-21	2006-10-26	Gastrotech Pharma A/S	Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
CN101166545B (zh)	2005-05-13	2011-06-15	伊莱利利公司	Glp-1聚乙二醇化的化合物
NZ565535A (en)	2005-06-30	2011-03-31	Ipsen Pharma Sas	GLP-1 pharmaceutical compositions
JP4994374B2 (ja) *	2005-07-29	2012-08-08	ジオファームオンコロジー，インコーポレイテッド	がんを治療するための化合物および方法
AU2006290227B2 (en)	2005-09-14	2012-08-02	Mannkind Corporation	Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
KR20080096809A (ko)	2006-02-22	2008-11-03	맨카인드 코포레이션	디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
CA2674209A1 (en) *	2006-12-29	2008-07-10	Ipsen Pharma S.A.S.	Glp-1 pharmaceutical compositions
WO2008134425A1 (en) *	2007-04-27	2008-11-06	Cedars-Sinai Medical Center	Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
KR20100090692A (ko) *	2007-10-24	2010-08-16	맨카인드 코포레이션	활성제의 전달
KR101736502B1 (ko) *	2007-10-24	2017-05-16	맨카인드 코포레이션	Ｇｌｐ-1에 의한 유해 효과의 예방 방법
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
SG10201507036TA (en)	2008-06-13	2015-10-29	Mannkind Corp	A dry powder inhaler and system for drug delivery
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
JP5604297B2 (ja)	2008-06-17	2014-10-08	株式会社糖鎖工学研究所	糖鎖付加ｇｌｐ−１ペプチド
EP2609954B1 (en)	2008-06-20	2021-12-29	MannKind Corporation	An interactive apparatus for real-time profiling of inhalation efforts
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (en)	2009-02-09	2010-08-11	Ipsen Pharma S.A.S.	GLP-1 analogues pharmaceutical compositions
MX2011009512A (es)	2009-03-11	2011-11-29	Mannkind Corp	Aparato, sistema y metodo para medir la resistencia de un inhalador.
US8614185B2 (en)	2009-05-04	2013-12-24	Centocor Ortho Biotech Inc.	Fusion proteins of alpha-MSH derivatives and Fc
EP2427204B1 (en)	2009-05-06	2017-04-05	Janssen Biotech, Inc.	Melanocortin receptor binding conjugates
MY157166A (en)	2009-06-12	2016-05-13	Mankind Corp	Diketopiperazine microparticles with defined specific surface areas
NZ597777A (en) *	2009-07-29	2013-03-28	Daiichi Sankyo Co Ltd	Motilin-like peptide compound having transmucosal absorbability imparted thereto
RU2012122162A (ru)	2009-10-30	2013-12-10	Глитек,Инк.	Гликолизированная форма аналога антигенного glp-1
CA2778698A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
US9168288B2 (en) *	2010-04-09	2015-10-27	Mount Sinai Hospital	Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
CA2797133C (en)	2010-04-27	2019-08-06	Zealand Pharma A/S	Peptide conjugates of glp-1 receptor agonists and gastrin and their use
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
RU2013103763A (ru)	2010-07-02	2014-08-10	Ангиохем Инк.	Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
PL2651398T3 (pl)	2010-12-16	2018-05-30	Novo Nordisk A/S	Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
EP2694402B1 (en)	2011-04-01	2017-03-22	MannKind Corporation	Blister package for pharmaceutical cartridges
DK2696687T3 (en)	2011-04-12	2017-02-06	Novo Nordisk As	Double-acylated GLP-1 derivatives
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
HK1200318A1 (en)	2011-10-24	2015-08-07	曼金德公司	Methods and compositions for treating pain
TW201326194A (zh)	2011-11-03	2013-07-01	Zealand Pharma As	Ｇｌｐ－１胃泌素受體促效劑肽結合物
PL3542790T3 (pl)	2012-03-22	2024-02-26	Novo Nordisk A/S	Kompozycje zawierające substancję dostarczającą i ich przygotowanie
HUE042757T2 (hu)	2012-03-22	2019-07-29	Novo Nordisk As	Szállító szert tartalmazó készítmények és elõállításuk
EP4324475A1 (en)	2012-03-22	2024-02-21	Novo Nordisk A/S	Compositions of glp-1 peptides and preparation thereof
JP6517690B2 (ja)	2012-06-20	2019-05-22	ノヴォノルディスクアー／エス	ペプチド及び送達剤を含む錠剤製剤
EP2872205B1 (en)	2012-07-12	2017-02-08	MannKind Corporation	Dry powder drug delivery systems
MX356957B (es)	2012-07-23	2018-06-20	Zealand Pharma As	Analogos del glucagon.
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
WO2014144895A1 (en)	2013-03-15	2014-09-18	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
KR20210086717A (ko)	2013-05-02	2021-07-08	노보 노르디스크 에이/에스	Glp-1 화합물의 경구 투여
KR102465025B1 (ko)	2013-07-18	2022-11-09	맨카인드 코포레이션	열-안정성 건조 분말 약제학적 조성물 및 방법
EP3030294B1 (en)	2013-08-05	2020-10-07	MannKind Corporation	Insufflation apparatus
CN104371019B (zh)	2013-08-13	2019-09-10	鸿运华宁（杭州）生物医药有限公司	一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
LT3057984T (lt)	2013-10-17	2018-12-27	Zealand Pharma A/S	Acilinti gliukagono analogai
AU2014345569B2 (en)	2013-11-06	2020-08-13	Zealand Pharma A/S	GIP-GLP-1 dual agonist compounds and methods
KR102310392B1 (ko)	2013-11-06	2021-10-13	질랜드 파마 에이/에스	글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
RU2716985C2 (ru)	2014-10-29	2020-03-17	Зилэнд Фарма А/С	Соединения-агонисты gip и способы
KR101825048B1 (ko)	2014-12-31	2018-02-05	주식회사 제넥신	GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
ES2833099T3 (es)	2015-02-11	2021-06-14	Gmax Biopharm Llc	Preparación de disolución estabilizada de una proteína de fusión de un anticuerpo de GLP-1R farmacéutica
JP6989385B2 (ja)	2015-04-16	2022-01-05	ジーランドファーマアクティーゼルスカブ	アシル化グルカゴン類似体
SG10201911851VA (en)	2016-12-09	2020-02-27	Zealand Pharma As	Acylated glp-1/glp-2 dual agonists
WO2019149880A1 (en)	2018-02-02	2019-08-08	Novo Nordisk A/S	Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
CN117003874A (zh)	2018-03-20	2023-11-07	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN112521501A (zh)	2019-09-18	2021-03-19	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
JP2025531814A (ja)	2022-09-08	2025-09-25	ジーマックスバイオファームエルエルシー	Ｇｉｐｒ抗体、ｆｇｆ２１との融合タンパク質、その医薬組成物及びその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY147327A (en) *	1995-06-29	2012-11-30	Novartis Ag	Somatostatin peptides
US5994500A (en) *	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides

1998
- 1998-06-11 SE SE9802080A patent/SE9802080D0/xx unknown
1999
- 1999-06-08 AT AT99930089T patent/ATE252912T1/de not_active IP Right Cessation
- 1999-06-08 DK DK99930089T patent/DK1094834T3/da active
- 1999-06-08 PT PT99930089T patent/PT1094834E/pt unknown
- 1999-06-08 EP EP20030024624 patent/EP1405642A1/en not_active Withdrawn
- 1999-06-08 HU HU0103147A patent/HUP0103147A3/hu unknown
- 1999-06-08 CA CA2321700A patent/CA2321700C/en not_active Expired - Fee Related
- 1999-06-08 RU RU2000133249/14A patent/RU2226402C2/ru not_active IP Right Cessation
- 1999-06-08 EP EP99930089A patent/EP1094834B1/en not_active Expired - Lifetime
- 1999-06-08 DE DE69912434T patent/DE69912434T2/de not_active Expired - Lifetime
- 1999-06-08 WO PCT/SE1999/000997 patent/WO1999064060A1/en not_active Ceased
- 1999-06-08 JP JP2000553128A patent/JP2002517468A/ja not_active Ceased
- 1999-06-08 CZ CZ20004491A patent/CZ300873B6/cs not_active IP Right Cessation
- 1999-06-08 NZ NZ506163A patent/NZ506163A/en unknown
- 1999-06-08 AU AU46697/99A patent/AU738994B2/en not_active Ceased
- 1999-06-08 PL PL343104A patent/PL198802B1/pl not_active IP Right Cessation
- 1999-06-08 US US09/445,571 patent/US6348447B1/en not_active Expired - Lifetime
- 1999-06-08 ES ES99930089T patent/ES2205845T3/es not_active Expired - Lifetime
2000
- 2000-08-10 ZA ZA200004080A patent/ZA200004080B/xx unknown
- 2000-12-06 NO NO20006194A patent/NO327738B1/no not_active IP Right Cessation
2010
- 2010-07-01 JP JP2010151403A patent/JP2010270125A/ja active Pending

Also Published As

Publication number	Publication date
DE69912434D1 (de)	2003-12-04
EP1094834A1 (en)	2001-05-02
NO327738B1 (no)	2009-09-14
ES2205845T3 (es)	2004-05-01
JP2002517468A (ja)	2002-06-18
ZA200004080B (en)	2001-12-24
RU2226402C2 (ru)	2004-04-10
AU738994B2 (en)	2001-10-04
HUP0103147A3 (en)	2002-02-28
CZ300873B6 (cs)	2009-09-02
CA2321700A1 (en)	1999-12-16
EP1405642A1 (en)	2004-04-07
PL198802B1 (pl)	2008-07-31
US6348447B1 (en)	2002-02-19
AU4669799A (en)	1999-12-30
SE9802080D0 (sv)	1998-06-11
PL343104A1 (en)	2001-07-30
NO20006194D0 (no)	2000-12-06
DK1094834T3 (da)	2004-01-05
DE69912434T2 (de)	2004-05-06
CZ20004491A3 (en)	2001-05-16
ATE252912T1 (de)	2003-11-15
EP1094834B1 (en)	2003-10-29
JP2010270125A (ja)	2010-12-02
HUP0103147A2 (hu)	2002-01-28
WO1999064060A1 (en)	1999-12-16
CA2321700C (en)	2011-05-03
PT1094834E (pt)	2004-03-31
NZ506163A (en)	2004-10-29

Legal Events

Date	Code	Title	Description
2013-02-04	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO20006194D0 (no)	2000-12-06	Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri
RU2000133249A (ru)	2002-11-27	Фармацевтическая композиция для лечения функциональной диспепсии и/или синдрома раздраженной толстой кишки и новое применение веществ в ней
NO984005L (no)	1998-08-31	Anvendelse av et farmas°ytisk preparat som omfatter et appetittundertrykkende peptid
FI954941A7 (fi)	1996-04-19	Glukagonintapaisia insuliinitrooppisia peptidianalogeja, koostumuksia ja käyttömenetelmiä
KR950002785A (ko)	1995-02-16	골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ATE316100T1 (de)	2006-02-15	Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
WO2003018516A3 (en)	2004-02-26	Glucagon-like peptide-1 analogs
WO2001068112A3 (en)	2002-03-07	Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
NZ334270A (en)	2000-07-28	Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
WO2002100390A3 (en)	2004-04-22	Improved method of treating the syndrome of coronary heart disease risk factors in humans
NO964548D0 (no)	1996-10-25	Substituerte sulfonamider som selektive 3 agonister for behandling av diabetes og fedme
ATE182078T1 (de)	1999-07-15	Laxiermittel das ballastfasern und dioctyl- sulfosuccinat enthält
NO20010982L (no)	2001-04-27	Fremgangsmåte for å administrere insulinotropiske peptider
FI943028L (fi)	1994-06-22	Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi
IS4510A (is)	1997-06-19	Peptíð p277 hliðstæður og lyfjasamsetningar sem innihalda þær, til meðhöndlunar eða sjúkdómsgreiningar á sykursýki
DK0425699T3 (da)	1994-11-21	Oralt præparat, der kan frigives i et passende område i tarmen
AU3733295A (en)	1996-05-02	Treatment of obstructive airway disease by administering thymosin beta 4, or coadministration of thymosin beta 4 and dnase i
WO2003092619A3 (en)	2004-10-07	Prevention and treatment of type 2 diabetes
SE8501202D0 (sv)	1985-03-11	Human intestinal hormone and its use
SE8501203D0 (sv)	1985-03-11	Mammal intestinal hormone precursor and its use
IT9048106A0 (it)	1990-07-03	Associazione medicamentosa per il trattamento dell'ipertensione e dell'insufficienza cardiaca congestiva. (caso 100-7516)
ATE237347T1 (de)	2003-05-15	Behandlung autoimmunerkrankungen in säugern
Bhatt et al.	2005	Appliccitions of external fixator devices in Post Burn Contracture of extremities
马连生 et al.	1994	COMBINATION OF TRADITIONAL CHINESE MEDICINE AND WESTERN MEDICINE IN THE TREATMENT OF RESISTANT PEPTIC ULCER
ECSP993116A (es)	1999-11-29	Procedimiento para administrar peptidos insulinotropicos